ER Positive, HER2 Negative Breast Cancer
Conditions
Brief summary
This is a phase II study evaluating the efficacy and safety of the pre-operative use of letrozole plus PD 0332991 (combination therapy)
Interventions
DRUGLetrozole, PD 0332991
Sponsors
Organisation for Oncology and Translational Research
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Postmenopausal women * Primary tumor greater than 2 cm in diameter * Histologically proven invasive breast cancer * Positive estrogen receptor * Negative HER-2 receptor * ECOG performance status ≤ 1 or Karnofsky performance status ≥ 70% * Laboratory values must be follows: Absolute neutrophil count ≥ 1,500/mm3; Platelets ≥ 100,000/mm3; Hemoglobin ≥ 9 g/dL; Bilirubin ≤ 1.5 × institutional upper limit of normal (ULN); Serum Creatinine ≤ 1.5 × ULN; Alkaline phosphatase ≤ 2 × ULN; AST and ALT ≤ 2 × ULN; Normal finding of ECG - QTc ≤ 470 msec (based on the mean value of the triplicate ECGs); Left ventricular ejection fraction (LVEF) ≥ 60%. * Able to give written informed consent form * Able to follow prescription instructions reasonably well
Exclusion criteria
* Male * Severe psychiatric disorder * Prior history of other malignancy within 5 years of study entry, aside from basal cell carcinoma or the skin or carcinoma-in-situ of the uterine cervix * Locally advanced breast cancer (T3N1 or Any T4 or Any N2, N3), or distant metastasis * Multifocal or multicentric breast cancer except that the largest lesion is greater than 2cm * Major surgery within 3 weeks of first study treatment * Current use or anticipated need for: Food or drugs that are known strong CYP3A4 inhibitors; drugs that are known strong CYP3A4 inducers * Severe cardiovascular diseases in the previous 6 months * Active inflammatory bowel disease or chronic diarrhea * Renal Impairment * Poor adrenal function * Hepatitis B and/or hepatitis C carriers (unless with normal hepatic function) * Known human immunodeficiency virus infection * Known hypersensitivity to anti-aromatase drugs or any cell cycle inhibitor * Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rates | Every 4 weeks before surgery |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants with Adverse Events | Continuous during the study, up to 28 days after the last treatment |
Other
| Measure | Time frame |
|---|---|
| Pathologic response rates | At time of definitive surgery |
Countries
China
Contacts
Primary ContactLouis Chow, MD
Outcome results
None listed